1st Jul 2015 08:22
LONDON (Alliance News) - Indivior PLC Wednesday said it plans to appeal a decision from the US Patent and Trademark Office regarding its US patent for its opioid dependence treatment Suboxone Sublingual Film.
Indivior said that of the 19 total claims included in the patent only five claims were challenged, and the Patent Trial and Appeal Board held that those five claims had been shown to be "unpatentable over certain prior art", meaning evidence the invention is already known.
"We remain confident in the strength of our intellectual property for Suboxone Film," said Chief Legal Officer Javier Rodriguez in a statement. "We disagree with this ruling and plan to appeal it to the Court of Appeals for the Federal Circuit."
The patent is one of five that is being asserted by Indivior in an ongoing litigation against a group of manufacturers looking to bring generic versions of Suboxone Film to market. Separately, Indivior said it had been given a new trial date of November 2 for its impending lawsuit against Watson Laboratories Inc and Par Pharmaceutical Inc as part of this patent litigation.
A second trial against Par Pharmaceutical is currently scheduled for December 2015.
Shares in Indivior, spun off from Reckitt Benckiser Group PLC last year, are trading up 0.8% at 226.60 pence Wednesday morning
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior